Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: an Italian inter-society consensus statement

• Váldodahkkit: Marcello Lanari (Dahkki), Elisabetta Venturini (Dahkki), Luca Pierantoni (Dahkki), Giacomo Stera (Dahkki), Guido Castelli Gattinara (Dahkki), Susanna Maria Roberta Esposito (Dahkki), Silvia Favilli (Dahkki), Emilio Franzoni (Dahkki), Eleonora Fusco (Dahkki), Paolo Lionetti (Dahkki), Claudio Maffeis (Dahkki), Gianluigi Marseglia (Dahkki), Laura Massella (Dahkki), Fabio Midulla (Dahkki), Alberto Zanobini (Dahkki), Marco Zecca (Dahkki), Alberto Villani (Dahkki), Annamaria Staiano (Dahkki), Luisa Galli (Dahkki), Other Collaborators (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: BMC, 2022-01-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract The fast diffusion of the SARS-CoV-2 pandemic have called for an equally rapid evolution of the therapeutic options. The Human recombinant monoclonal antibodies (mAbs) have recently been approved by the Food and Drug Administration (FDA) and by the Italian Medicines Agency (AIFA) in subject...